The Russian pharmaceutical sector is roaring forward, estimated to reach a value of $10.7 billion by 2014 and $60 billion by 2020, fueled by the Russian Government’s initiatives to bolster the country’s domestic pharmaceutical market. Rafarma Pharmaceuticals aims to take its fair share of the market and emerge as one of the Top 3 Russian pharmaceutical companies within the next decade.
To reach this goal, Rafarma has built a new world-class 270,000 square-foot manufacturing plant in a strategic location and operated by a highly classified management team.
A recent video published by QualityStocks Productions highlights Rafarma’s position in the burgeoning industry, its stellar production facility, and how the company has contributed to the economic growth in Russia.
“The Russian Federation has expressed great interest in entering the big pharma initiative. With this initiative, Rafarma is poised and place in a location and in a way that we believe Rafarma will enter that big pharma market,” Dave Anderson, CEO of Rafarma’s USA Operations, says in the video.
Rafarma’s manufacturing facility is located in Terbuny, Lipetsk Region, Russia, positioned to raise the economic standard of the area and employ local citizens under the leadership of experienced a director and team of engineers.
Armed with skilled and trained employees, the company’s facility is comprehensive in its capabilities.
“It’s not just a manufacturing facility. It’s also developmental labs,” says Jack Brannelly, outside counsel for Rafarma. “They create their own products and patent those products here. But they also have the capacity to manufacture for other companies. They can create generic drugs.”
From its technologically advanced facility, Rafarma is positioned to modernize Russia’s domestic medical/pharmaceutical industry, leveraging the Russian government’s aggressive strategy. What differentiate Rafarma from its peers are its state-of-the art facility and industry qualifications.
“Rafarma has been given the highest qualifications in the international standards. This sets us apart from many other pharmaceutical companies and allows us to be able to provide that excellent service,” says Anderson.
For more information, visit www.rafarma.us
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment